Guardant Health Enters Material Definitive Agreement

Ticker: GH · Form: 8-K · Filed: 2024-08-23T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement

TL;DR

Guardant Health signed a big deal, details TBD.

AI Summary

Guardant Health, Inc. announced on August 23, 2024, that it has entered into a material definitive agreement. The filing does not disclose specific details of the agreement, the counterparty, or any associated financial figures. Further information is expected to be provided in subsequent filings or exhibits.

Why It Matters

This filing indicates a significant new business development for Guardant Health, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in this 8-K filing creates uncertainty about the nature and implications of the material definitive agreement.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Guardant Health?

The filing does not specify the nature of the material definitive agreement.

Who is the counterparty to this material definitive agreement?

The filing does not disclose the identity of the counterparty.

Are there any financial terms or obligations associated with this agreement?

The filing does not provide any details regarding financial terms or obligations.

When was the agreement officially entered into?

The report indicates August 23, 2024, as the date of the earliest event reported, which is presumed to be the entry into the agreement.

Where can I find more details about this agreement?

Further details are expected to be disclosed in exhibits or subsequent filings, as indicated by the filing type.

From the Filing

0001193125-24-206179.txt : 20240823 0001193125-24-206179.hdr.sgml : 20240823 20240823161054 ACCESSION NUMBER: 0001193125-24-206179 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20240823 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240823 DATE AS OF CHANGE: 20240823 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 241236434 BUSINESS ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 8-K 1 d870565d8k.htm 8-K 8-K false 0001576280 0001576280 2024-08-23 2024-08-23     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 23, 2024     GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter)       Delaware   001-38683   45-4139254 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (IRS Employer Identification No.) 3100 Hanover Street Palo Alto , California 94304 (Address of principal executive offices) (Zip Code) 855 - 698-8887 (Registrant’s telephone number, include area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.00001 par value per share   GH   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01 Entry into a Material Definitive Agreement. Open Market Sale Agreement On August 23, 2024, Guardant Health, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (the “Agent”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), having aggregate gross proceeds of up to $400.0 million (the “Shares”) through the Agent, acting as sales agent. Any Shares to be offered and sold un

View on Read The Filing